Trading Symbol: QM4
Toronto, Ontario–(Newsfile Corp. – October 12, 2023) – Safe Supply Streaming Co. Ltd. (CSE: SPLY) (FSE: QM4) (“Safe Supply” or “Company“), the first company investing in and incubating companies at the forefront of the third wave of drug policy reform, is pleased to announce that effective today it begins trading on the Frankfurt Stock Exchange (“FSE“) under the symbol “QM4”. Safe Supply’s FSE information can be found on the Börse Frankfurt website: https://www.boerse-frankfurt.de/equity/safe-supply-stre-co-ltd-1.
“Our mission at Safe Supply is to help bring a responsible end to the war on drugs, which has been a misguided global policy for over 50 years. So, it is important for us that all people everywhere have an opportunity to invest in helping bring it to an end,” said Bill Panagiotakapoulos, Safe Supply’s CEO. “This is one of the reasons we are so pleased to now be listed on the FSE. Not only will it enhance liquidity for our current investors, it will also invite more people around the world to participate in this important conversation and incredible global investment opportunity.”
The Frankfurt Stock Exchange is a European trading platform and the largest of the seven stock exchanges in Germany. The new listing helps facilitate the purchase and trading of Safe Supply’s shares for European investors with low transaction costs.
With the commencement of trading on the FSE, the Company will now be available for trading on two marketplaces around the world — the Canadian Securities Exchange (“CSE“) and the Frankfurt Stock Exchange (“FSE“). The Company plans to seek listings on additional exchanges in the future.
About Safe Supply
With a mission to help bring a responsible end to the war on drugs, Safe Supply Streaming Co. Ltd. is investing in and incubating companies at the forefront of the third wave of drug policy reform. As jurisdictions around the world move to decriminalize, regulate and legalize drugs, Safe Supply is investing in the infrastructure necessary to support the transition. From developing the facilities to analyze, manufacture and distribute psychoactive compounds including the coca plant, to investing in the research and innovation to harness the potential, and minimize the harm, of these medicines, to constructing the clinical infrastructure to ensure safe and responsible access and treatment, Safe Supply is building a platform of tightly woven companies that will help save millions of lives and build a safer, healthier post-war on drugs worlds.
Learn more at www.safesupply.com and follow Safe Supply on LinkedIn, Twitter, and Instagram.
For Further Information:
Bill Panagiotakopoulos
Chief Executive Officer and Director
Safe Supply Streaming Co. Ltd.
www.safesupplystreaming.com
bill@safesupply.com
Media contacts:
McKenna Miller
KCSA Strategic Communications
safesupply@kcsa.com
Forward-Looking Information and Statements
Certain statements in this news release related to Safe Supply and Origin are forward-looking statements and are prospective in nature, including but not limited to the express or implied statements and assumptions regarding the intention of Origin and Safe Supply to complete the Transaction. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These forward-looking statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe”, “will” or “continue”, or the negative thereof or similar variations. There are numerous risks and uncertainties that could cause actual results and Origin’s and Safe Supply’s plans and objectives to differ materially from those expressed in the forward-looking information, including but not limited to adverse market conditions and risks inherent in Origin’s and Safe Supply’s respective businesses. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this press release. Except as required by applicable law, Origin and Safe Supply do not intend to update these forward-looking statements. Without limiting the generality of the foregoing, there can be no assurance that the Transaction will be completed as proposed, or at all. Investors are cautioned that, except as disclosed in the management information circular and/or listing statement to be prepared in connection with the Transaction, any information released or received with respect to the Transaction may not be accurate or complete and should not be relied upon. Trading in the securities of Origin should be considered highly speculative.
The CSE has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.
None of the securities to be issued in connection with the Transaction have been, or will be, registered under the United States Securities Act of 1933, as amended (the “1933 Act“), or any state securities laws, and may not be offered or sold within the United States or to any U.S. Person (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws or an exemption from such registration is available. This press release does not constitute an offer to sell or a solicitation of an offer to sell any securities in any jurisdiction where such offer or solicitation would be unlawful, including the United States.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/183790
WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…
WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…
New leadership roles highlight Hallmark’s unique vendor-neutral approach to helping health systems build flexible, efficient,…
Company Celebrates Continued Worldwide Progress Toward Data-Driven Surgery SAN FRANCISCO and BERLIN, Dec. 23, 2024…
SEOUL, South Korea, Dec. 23, 2024 /PRNewswire/ -- Medit has launched a mobile app, MEDIT…
EX Program by Truth Initiative Offers a Proven Path to Success WASHINGTON, Dec. 23, 2024…